Example SOP for New Product Introduction

In short: This illustrative SOP template helps a site plan a new product, product transfer or manufacturing change. A cross-functional team should assess feasibility and risk, transfer the necessary product and process knowledge, and document readiness of people, materials, methods, facilities and equipment before execution. Adapt the gates and approvals to the product lifecycle, applicable regulatory pathway and site quality system.

1. Purpose

To describe a site-adaptable process for assessing, planning, transferring, introducing and reviewing a new product or product/process transfer at a manufacturing location.

2. Scope

This example SOP covers products developed at the site, products or methods transferred from another location or company, and products entering a new manufacturing process or site. Define whether development, exhibit, engineering, validation, commercial or contract-manufacturing activities are in scope and which separate procedures govern them.

Related procedures include Process validation in the pharmaceutical industry, Validation master plan, SOP for batch release of finished product and SOP on receipt and issue control of laboratory chemicals.

3. Responsibilities

• Project sponsor / management: confirms business priority, resources and project ownership.
• Project lead: maintains the project plan, cross-functional actions, decisions, risks and readiness status.
• Quality Assurance (QA): oversees change control and quality-system coordination, reviews quality risks and required documentation, and approves site readiness within assigned authority.
• Regulatory Affairs: assesses the applicable product, site and market regulatory pathway and manages regulatory submissions, commitments and communications.
• Quality Control (QC): assesses specifications, analytical methods, reference materials, laboratory capacity, method transfer and testing or stability-study support.
• Production: assesses process fit, batch documentation, personnel, training, capacity and execution readiness.
• Engineering / Validation: assesses facilities, utilities, equipment, maintenance, qualification and validation needs.
• Supply Chain / Procurement / Warehouse: assesses sourcing, supplier qualification, materials planning, receipt, storage and status controls.
• Other functions: Microbiology, Packaging, EHS, IT and external partners contribute when relevant to the product and risk assessment.

4. Procedure

4.1 Initiation and project scope

1. Start a controlled project or change record before implementation. Identify the product, dosage form, intended site and markets, development or lifecycle stage, project sponsor, project lead, affected processes and proposed target outcomes.
2. Identify whether the work is a new product, transfer from a sending unit, change to an existing product/process, or a combination. For a transfer, identify sending and receiving units and define their responsibilities and information-sharing arrangements.
3. Establish a cross-functional team and a documented plan covering activities, dependencies, decisions, records, deliverables, unresolved questions and readiness gates. Scale the plan to the stage and complexity of the work.
4. Apply documented quality risk management to product and process knowledge, materials, premises, equipment, methods, manufacturing, QC, validation, supply and regulatory aspects. Set actions and acceptance criteria before execution and review risks as knowledge changes.

WHO’s technology-transfer guidance describes transfer as a planned, documented process between sending and receiving units, with documented evidence that the receiving unit can reproduce the transferred product, process or procedure to predefined specifications. It also says risk-management effort should be commensurate with risk. See WHO TRS 1044, Annex 4 (2022) and ICH Q9(R1) (2023; minor typographical correction 2025).

4.2 Feasibility and gap assessment

1. Review the available product and process knowledge, development reports, formula or composition, manufacturing instructions, analytical procedures, specifications, packaging information, stability data, safety information, regulatory commitments and prior deviations or changes, as applicable.
2. Compare requirements with site capabilities. Assess premises and flows, equipment and tooling, utilities, environmental controls, process capacity, QC and microbiology methods, data systems, personnel competence, suppliers, materials, storage and transport.
3. Identify gaps, quality risks, regulatory questions, required investment or external services, and proposed mitigations. Document accountable owners, due dates and evidence needed to close each gap.
4. Decide whether the site can proceed, proceed after defined actions, or stop and escalate. Document approvals and the rationale in the controlled project/change record.

4.3 Regulatory, quality and technical planning

1. Regulatory Affairs determines which authorizations, filings, notifications, commitments, labelling or other regulatory actions may apply to the product, site, manufacturing activity and target markets. Confirm the requirements with the relevant authority or qualified regulatory counsel where needed; record the basis and status.
2. QA coordinates applicable change control and identifies required quality documents. Prepare or update specifications, methods, material controls, product quality documentation, batch records, packaging records and associated procedures through document control.
3. Define the technology-transfer plan and agreement, where relevant. Agree on the transferred knowledge, documentation, data, roles, acceptance criteria, deviations, confidentiality and report. Perform a gap analysis between sending and receiving units.
4. Define the strategy and protocols for analytical procedure transfer, process validation, cleaning assessment or validation, equipment/facility qualification and stability studies, as applicable. The scope and sequence depend on product knowledge, lifecycle stage, risk and applicable requirements; this SOP does not set universal batch counts or acceptance limits.
5. Define the training and qualification needs for personnel who prepare, manufacture, sample, test, package, review or release the product.

4.4 Readiness of site, equipment, suppliers and materials

1. Engineering and Validation assess whether facilities, utilities and equipment are suitable for the intended product and process. Complete required installation, qualification, calibration, maintenance and operating/cleaning procedures before use.
2. Production, Engineering and EHS review process hazards, containment, occupational exposure, waste, cleaning and emergency controls and ensure appropriate site assessments are completed.
3. Qualify or approve suppliers and contract laboratories under site procedures. Confirm material specifications, methods, supply continuity, quality agreements where relevant, and required supplier documentation.
4. QC ensures that equipment, qualified methods, standards, reagents, reference materials, trained analysts and laboratory capacity are available. Complete method transfer, verification or validation as justified and approved.
5. Regulatory Affairs, QA, Packaging and other relevant functions review product and packaging information and required artwork or labelling controls. Approve controlled documents before use.
6. Warehouse and Supply Chain define receipt, sampling, testing, status labelling, storage, inventory and transport arrangements for starting, packaging and finished materials.

4.5 Execution, review and launch readiness

1. Execute approved development, transfer, engineering, exhibit or validation activities under approved protocols and records. Document actual results, deviations, investigations, changes and decisions.
2. QA and the responsible functions review results against predefined acceptance criteria. Resolve or formally assess deviations and outstanding risks before progression to the next project gate.
3. Before routine or commercial manufacture, document that applicable regulatory prerequisites are satisfied, required facilities/equipment and methods are ready, personnel are trained, materials and suppliers are approved, batch documentation is effective, and required qualification/validation and stability plans are approved or complete as appropriate to the intended stage.
4. Obtain documented approvals from QA, Regulatory Affairs and relevant function owners under the site’s authority matrix. Do not treat management or marketing approval alone as evidence of regulatory or quality readiness.
5. Monitor initial manufacture and product/process performance under approved quality-system procedures. Evaluate issues and update the risk assessment, controls and project records as needed.

4.6 Project close-out and lifecycle follow-up

1. Prepare a close-out or transfer report summarizing the scope, activities, results, deviations, residual risks, approvals and conclusion against acceptance criteria.
2. Ensure controlled documents, data, training records, supplier records, validation reports, regulatory records and product knowledge are filed and retrievable.
3. Transfer ongoing responsibilities to the designated product and process owners. Track open actions through completion and review relevant product and process performance through the pharmaceutical quality system.

5. Source-template practices for Admin verification

The source contains these example in-house criteria for review. They are not universal requirements and should be retained only if aligned with current site procedures and authority assignments.

• The source requires QA to open change control for every new product and describes marketing/top management as deciding whether a product is introduced. Example in-house criterion: management or marketing may decide on business priority and sponsorship, but this does not replace the Quality and Regulatory decisions. Under the pharmaceutical quality system (ICH Q10) and the site’s change-control procedure, QA must evaluate and approve the project or change record, and Regulatory Affairs must confirm the regulatory pathway, before any implementation. Commercial approval alone is never sufficient to introduce a product.
• The source says QA receives technical information from QC and applies for a manufacturing licence from the State FDA. Regulatory Affairs, together with QA, should confirm the current Indian licensing pathway (Drugs and Cosmetics Act and Rules, as administered by CDSCO and the State Licensing Authority) for each product, site and activity. Assign the application and approval responsibilities in the site procedure accordingly; the application is normally prepared by Regulatory Affairs with technical input from QA, QC, Production and Engineering.
• The source assigns QA sole responsibility for executing and compiling process validation, and QC sole responsibility for stability studies. Correction: responsibilities are shared. Production, Engineering/Validation and QC typically execute process, cleaning and qualification activities and testing; QA reviews and approves the protocols, deviations and reports. QC (or an approved contract laboratory) performs stability testing under an approved protocol, with QA approval and Regulatory Affairs input on commitments. Assign the exact roles in the governing validation and stability procedures (see ICH Q10 on management responsibility and the pharmaceutical quality system).
• The source directs that all listed steps for new products also be applied to site transfers and requires a checklist with final QA comment and signature before manufacturing. Correction: a site transfer needs a transfer-specific plan, a sending/receiving unit gap analysis, a written agreement (including quality agreements where a contract party is involved) and an approved checklist or report with QA sign-off before routine manufacture (WHO TRS 1044, Annex 4). The extent of each step is scaled to lifecycle stage and risk (ICH Q9(R1)); not every new-product step applies unchanged to every transfer.
• The source includes exhibit batches, validation batches, first commercial batches, vendor qualification, printed artwork, technology-transfer dossiers and contract laboratories in one workflow. Correction: treat these as separate gates with named owners. Regulatory prerequisites (for example, approvals needed before exhibit or commercial batches) must be confirmed by Regulatory Affairs before the relevant stage. Contract laboratories require qualification and a written quality agreement, and QA approves suppliers. Artwork and labelling are released only through controlled document approval by QA and Regulatory Affairs. Stage-specific gates are defined in the site’s validation, supplier-qualification and change-control procedures.

6. Abbreviations

• API: active pharmaceutical ingredient
• EHS: Environment, Health and Safety
• QC: Quality Control
• QA: Quality Assurance
• RU: receiving unit
• SU: sending unit

References

• World Health Organization (WHO), WHO guidelines on technology transfer in pharmaceutical manufacturing, WHO Technical Report Series No. 1044, Annex 4, 2022. Official guideline
• International Council for Harmonisation (ICH), Pharmaceutical Quality System, Q10, Step 4, 2008. Official guideline
• International Council for Harmonisation (ICH), Quality Risk Management, Q9(R1), adopted 18 January 2023; minor typographical correction 15 January 2025. Official guideline